CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2011-02-02): Mycophenolate mofetil helps avoid steroids for autoimmune hepatitis

Drug & Device Development

Mycophenolate mofetil helps avoid steroids for autoimmune hepatitis

Last Updated: 2011-02-02 16:58:24 -0400 (Reuters Health)

NEW YORK (Reuters Health) - Mycophenolate mofetil appears particularly safe and effective in treatment-naive patients with autoimmune hepatitis, Greek researchers report.

Dr. George N. Dalekos of the University of Thessaly, Larissa and colleagues note that patients ordinarily receive corticosteroids with or without azathioprine. About 20% of patients do not respond or are intolerant.

Moreover, steroid associated side effects are significant. And at least 10% of patients taking azathioprine develop nausea, vomiting, rash, cytopenia, pancreatitis or cholestasis.

The Greek team treated 59 patients with prednisolone plus mycophenolate mofetil, 1.5 to 2 g/day. Primary end points were treatment response (complete, partial or no response or relapse), and secondary end points were the improvement of AST, ALT, gamma globulins and/or serum levels from baseline to the end of treatment, and the incidence of steroid withdrawal.

Fifty-two patients (88%) had complete biochemical and clinical responses, usually within 3 months. The remaining 7 patients had partial responses, the authors reported online January 14th in the Journal of Hepatology.

Mean mycophenolate treatment duration was 26 months. In total, 59.3% had complete responses without relapse, and 37.0% did so off of prednisolone. A further 28.8% had an initial complete remission with relapses.

Corticosteroids were withdrawn in 34 patients (57.6%) after a median of 8 months. In the 43 patients who were treated for more than 12 months, the frequency of prednisolone withdrawal was 70%.

Severe side effects leading to mycophenolate discontinuation occurred in only 2 patients, both of whom had septicemia. Overall, 6 patients stopped mycophenolate treatment, but 3 relapsed.

Given these favorable results, the team stresses that mycophenolate mofetil "has to be rigorously investigated as potentially the preferable first-line therapy for the treatment of autoimmune hepatitis."

In fact, they conclude that there's an urgent need "to confirm definitely the potential advantage of mycophenolate mofetil-based treatment."

SOURCE: http://bit.ly/hUDtKn

J Hepatol 2011.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.